Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans for a pivotal genetic predisposition study aimed at uncovering key immunologic factors contributing to Long COVID development.

Tevogen's groundbreaking ExacTcell platform, engineered to harness the potent cytotoxicity of T lymphocytes (CTLs), is poised to revolutionize Long COVID treatment. TVGN 489, a CTL therapy derived from the ExacTcell platform, has demonstrated promise in recognizing multiple protein targets across the SARS-CoV-2 genome, exhibiting favorable tolerability in high-risk acute COVID-19 patients.

In a bold move, Tevogen embarks on a pioneering study to evaluate the role of Human Leukocyte Antigens (HLA) in Long COVID predisposition. By assessing the correlation between HLA types and Long COVID occurrence, Tevogen aims to elucidate whether certain HLA variants confer heightened susceptibility or resilience to Long COVID. This crucial insight will inform the development of tailored CTL products targeting HLA types associated with Long COVID susceptibility, paving the way for expedited Long COVID treatment trials.

Dr. Neal Flomenberg, Tevogen's Chief Scientific Officer, expressed optimism about TVGN 489's potential to address the acute and chronic phases of COVID-19, citing the therapy's robust target profile and enduring efficacy. The forthcoming genetic predisposition study is poised to provide invaluable insights into the immunological underpinnings of Long COVID, setting the stage for transformative treatment advancements.

Shannon Rudolph, Clinical Scientist at Tevogen, emphasized the significance of the genetic predisposition study in elucidating Long COVID pathogenesis and streamlining treatment trial development. By unraveling the intricate interplay between HLA types and Long COVID susceptibility, Tevogen endeavors to accelerate the delivery of effective Long COVID therapies to patients in need.

Tevogen Bio Holdings Inc. remains steadfast in its commitment to pioneering cellular therapies and driving innovation in the fight against COVID-19, with a singular focus on alleviating the burden of Long COVID and restoring health and vitality to affected individuals.